Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1626 1629 1674
This examiner grants 87% of resolved cases
Golam M. Shameem has processed 895 resolved cases in Art Unit 1621. The examiner maintains an allowance rate of 86.7 percent. This figure provides a baseline for applicants to understand the probability of a grant in Tech Center 1600. The data shows an interview lift of 16.0 percent. This lift represents the difference in allowance rates between cases with and without interviews. Practitioners should consider this 16.0 percent lift when deciding whether to engage in direct communication.
The median days to allowance for this examiner is 687. This duration represents the timeline for reaching a final resolution for the 895 resolved cases. Applicants in Art Unit 1621 can use this 687-day metric to plan their prosecution schedules. The 86.7 percent allowance rate indicates the frequency of grants for this profile. With an interview lift of 16.0 percent, the role of the interview is a documented factor in the examiner's history. These metrics provide a view of the prosecution environment for this profile in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18762951 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | Non-Final OA | The General Hospital Corporation |
| 18949084 | THERAPEUTIC COMPOUNDS | Non-Final OA | Sanofi |
| 18682031 | SELECTIVE PSYCHEDELIC COMPOUNDS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18762851 | PHARMACEUTICAL COMPOSITIONS FOR USE IN REDUCING HYPERPIGMENTATION | Non-Final OA | Caliway Biopharmaceuticals Co., Ltd. |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | Non-Final OA | Seagen Inc. |
| 18039900 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | Non-Final OA | S-Form Pharma |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy